were assessed in Langendorff perfused hearts during 20 min ischemia and 45 min reperfusion. In control hearts ventricular pressure development recovered to 68±4 mmHg (63±3% of baseline), diastolic pressure remained elevated (23±2 mmHg), and 26±4 U/g lactate dehydrogenase (LDH) was released during reperfusion, evidencing necrosis. Treatment with 250 nM UTP improved pressure development (85±5 mmHg, or 77±2%), and reduced diastolic contracture (by ~70%, to 7±1 mmHg) and LDH loss (by ~60%, to 11±2 U/g). In contrast, P2Y 1 agonism with 50 nM 2-methyl-thio-ATP
INTRODUCTION
Extracellular nucleotides may play important regulatory roles within the cardiovascular system (Kunapuli and Daniel, 1998; Vassort, 2001) , with recent evidence implicating P2 purinergic receptors in protection of ischemic or reperfused myocardium (Vassort, 2001; Ninomiya et al., 2002a Ninomiya et al., , 2002b . While purine nucleotides have been the most widely studied P2 agonists, it is clear pyrimidines such as UTP also possess important regulatory functions. Two recent studies provide evidence UTP may mediate protective actions in ischemic hearts (Yitzhaki et al., 2006) and hypoxic myocytes (Yitzhaki et al., 2005) from rats. However, not all investigations detect such effects of UTP under similar conditions (Ninomiya et al., 2002a) , and a number of issues arise from prior studies, foremost among these being use of very high UTP concentrations to trigger protection (Ninomiya et al., 2002a; Yitzhaki et al., 2005) . These prior studies employ levels >2-orders of magnitude above those required to activate the P2Y 2 receptors implicated in the responses (von Kugelgen and Wetter, 2000; Jacobson et al., 2002 , von Kugelgen, 2006 . The physiological (even pathological) relevance of responses to such high agonist levels is questionable, and it is difficult to ascribe effects to specific receptor sub-types, since such concentrations will even activate P2 receptors classified as UTP insensitive (eg. P2Y 1 receptors). Additionally, in the only study of intact perfused hearts (Ninomiya et al. 2002a ) myocyte death was not assessed, and the primary measure of ischemic outcome (contractile recovery) was complicated by uncontrolled and thus variable heart 6 JPET #125815 body weight, n=119) anesthetized with 50 mg/kg sodium pentobarbital administered intraperitoneally. After a thoracotomy, hearts were excised into ice-cold perfusion buffer, the aorta cannulated and perfused at 80 mmHg with a Krebs-Henseleit buffer containing (mM): NaCl, 118; NaHCO 3 , 25; KCl, 4.7; KH 2 PO 4 , 1.2; CaCl 2 , 2.5; Mg 2 SO 4 , 1.2; glucose, 11; pyruvate, 2; and EDTA, 0.5. Buffer was equilibrated with 95% O 2 , 5% CO 2 at 37°C, giving a pH of 7.4. The left ventricle was vented with a polyethylene drain and a fluid-filled balloon inserted into the ventricle via the mitral valve. The balloon was connected to a pressure transducer for measurement of ventricular pressure. Hearts were immersed in perfusate at 37°C and the ventricular balloon inflated to generate a diastolic pressure of ~5 mmHg. Coronary flow was monitored via a Doppler flow-probe (Transonic Systems Inc., Ithaca, NY, USA) in the aortic perfusion line. Functional parameters were measured and recorded on a 4 channel MacLab unit (ADInstruments, Castle Hill, Australia).
Experimental Protocol. Hearts stabilized for 20 min at intrinsic heart rate were switched to ventricular pacing at 420 beats/min (2 ms pulse duration, amplitude 20% above the pacing threshold) for a further 10 min. Baseline function was then assessed and 20 min global ischemia initiated followed by 45 min reperfusion. Pacing was terminated during ischemia and reinstated at 2 min reperfusion (Headrick et al., 2001; Peart and Headrick, 2003) . Hearts were either untreated (n=19), or subjected to P2 purinoceptor antagonism (200 µM suramin, 100 µM RB-2, 50 µM PPADS, or 30 µM MRS2159) applied 15 min prior to ischemia and for the initial 10 min of reperfusion (n=8 for each drug), P2 purinoceptor agonism with 250 nM UTP (applied 10 min prior to ischemia and for the initial 10 min of reperfusion; n=12), or co-treatment with UTP+suramin (n=8) according to the same protocols. Upon detection of significant effects of both 200 µM suramin and 100 µM RB-2 on intrinsic ischemic tolerance (see RESULTS), we subsequently assessed effects of lower 10 µM concentrations of these antagonists applied alone (n=7 for suramin, n=7 for RB-2), and of 10 µM suramin + 250 nM UTP (n=9). We additionally studied P2Y 1 agonism with 50 nM 2-MeSATP 7 JPET #125815 (n=11). As we were principally interested in identifying whether P2 agonism (or antagonism) might modify responses to ischemic insult, we employed drug infusion protocols effectively bracketing the ischemic episode and early reperfusion.
For assessment of necrotic cell death, we measured efflux of the intracellular enzyme LDH (Headrick et al., 2001; Peart and Headrick, 2003; Reichelt et al., 2005) . Myocardial LDH efflux has been shown to correlate linearly with infarct size in this model (Peart and Headrick, 2003) . Coronary effluent was collected on ice and stored at -80°C (≤7 days) until analysis for LDH via a CytoTox assay kit (Promega Corporation, Annandale, Australia), a colorimetric assay coupling LDH content to conversion of a tetrazolium salt to a colored formazan product. Total LDH washed from hearts during reperfusion was calculated as the product of LDH content (per ml) and total coronary effluent over the measurement period (Headrick et al., 2001; Peart and Headrick, 2003) .
Cardiac Microdialysis Assessment of Interstitial Nucleotides. To test for elevations in
endogenous P2 agonists in the interstitial compartment, a second group of untreated hearts (n=14) was instrumented with cardiac microdialysis probes according to the method outlined by us previously (Peart and Headrick, 2000) . Probes were constantly perfused at 1 µl/min and eluents collected on ice over 10 min periods. After a 60 min stabilization period half of these hearts were subjected to 20 min global ischemia and 45 min reperfusion while the remainder were perfused normally (non-ischemic control). Consecutive 10 min samples of dialysate were collected and frozen at -80°C until analyzed via HPLC, using an adaptation of prior techniques (Headrick and Willis, 1989; Harrison et al., 1998) . Briefly, dialysate samples were injected onto a Suplecosil C18S column (maintained at 27°C) and eluted at 1 ml/min using a buffer gradient (60% solution A/40% solution B at 0 min to 40% solution A/60% solution B at 25 min, followed by isocratic elution to 60 min).
Solution A consisted of a 10 mM KH 2 PO 4 buffer containing 0.25% MeOH and 10 mM tetrabutylammonium hydroxide (pH 6.9), and solution B consisted of a 50 mM KH 2 PO 4 buffer This article has not been copyedited and formatted. The final version may differ from this version. Treatment with UTP failed to modify ventricular contractile function in normoxic hearts. Similarly, most antagonist treatments did not alter contractility, although 100 (but not 10) µM RB-2 did generate a significant increase in force development and inotropic state (Table 1) . Interestingly, suramin (at 200 µM) and RB-2 (at both 10 and 100 µM) generated significant elevations in baseline coronary flow, while there was a tendency (albeit insignificant) for modestly decreased coronary flow with UTP (Table 1) . Diastolic pressure remained elevated at ~20 mmHg (Fig. 1A) , and ventricular pressure development recovered to ~65% of pre-ischemic levels (Fig. 1B) . Coronary flow recovered to slightly less than pre-ischemic levels ( Fig. 2) , reflecting necrotic death (Peart and Headrick, 2003) .
Effects of Ischemia and UTP on
Treatment of hearts with 250 nM UTP significantly reduced post-ischemic diastolic dysfunction, and moderately enhanced ventricular pressure development (Fig. 1 ). These effects were not associated with significant differences in final recovery of flow rate (expressed as ml/min/g; Fig.   1C ). Treatment with UTP also significantly reduced LDH loss (Fig. 2) . We additionally tested for effects of the P2Y 1 agonist 2-MeSATP (50 nM), but the agent was found to exert no effects on any markers of ischemic injury at this concentration (data not shown). To test for P2 involvement in UTP-mediated cardioprotection we co-treated hearts with the antagonist suramin, which was found to exert concentration-dependent effects on ischemic outcome. When applied at 200 µM, suramin worsened functional recovery from ischemia ( Fig. 1 ) and LDH washout (Fig. 2 ). However, a lower 10 µM concentration was without effect on functional recovery from ischemia ( Based on apparent reduction in ischemic tolerance with 100 µM suramin alone, we assessed release of P2 agonists into the interstitial compartment (Fig. 3) . Under normoxic conditions we were able to detect ATP in most cases, yet could not consistently detect ADP or UTP in cardiac microdialysate samples (Fig. 3) . However, during 20 min of global ischemia the accumulation of all three nucleotides was significantly enhanced, with ATP levels exceeding those for ADP, and in turn UTP.
Nucleotide concentrations peaked within the initial 10 min of ischemia and then declined during the ensuing 10 min (although remaining substantially elevated above normoxic levels). Subsequent reperfusion led to a gradual decline in dialysate UTP, ATP and ADP levels, such that only ATP detected in normoxically perfused hearts (Fig. 3) .
Effects of P2 Purinoceptor Antagonism on Functional Tolerance to Ischemia. To determine whether accumulation of endogenous nucleotides in the interstitium might indeed modify functional outcome from ischemia we re-assessed contractile responses to ischemia-reperfusion in the presence of differing P2 antagonists (Fig. 4) . As already noted, treatment with 200 µM suramin worsened post-ischemic outcome, increasing diastolic dysfunction and limiting recovery of ventricular pressure development (Figs. 1 and 4) and enhancing cell death (Fig. 2) . Greater contractile dysfunction was accompanied by impaired recovery of coronary flow (to ~65%) (Fig.   4C ). The alternate P2 antagonist RB-2 (at 100 µM) also worsened contractile dysfunction.
Interestingly, while a lower 10 µM concentration of RB-2 also worsened ischemic outcomes, this concentration of suramin was without effect on post-ischemic functional recovery (Fig. 4) , though it remained effective in blocking the protective effects of UTP (Fig. 1) . Neither 10 µM PPADS or 30 µM MRS2159 exerted any effect on post-ischemic recoveries (Fig. 4) 
DISCUSSION
Recent studies provide good support for UTP-dependent cardioprotection in the rat (Yitzhaki et al., 2005 (Yitzhaki et al., , 2006 . However, these findings are not universal (eg. Ninomiya et al., 2002a) , and a number of interesting questions arise from these prior investigations. Here we confirm P2-mediated cardioprotection in response to sub-micromolar concentrations of UTP, document significant accumulation of UTP (together with ATP and ADP) in the interstitium of ischemic hearts, and show that high levels of the P2 antagonists suramin and RB-2 (and not PPADS or MRS2159) worsen ischemic outcome. Interestingly, while a lower 10 µM concentration of RB-2 also limited postischemic outcome, suramin at this concentration was ineffective. Collectively, these findings JPET #125815 evidence cardioprotection via exogenous UTP (involving limitation of ventricular contractile dysfunction and necrosis), and implicate the P2Y 2 receptor as the most likely mediator of this protection. Mixed effects of P2 antagonists alone also support protection via endogenous P2 agonists, though these responses may potentially involve P2-independent effects and deserve further attention (see below).
P2 Purinoceptors and Cardioprotection.
Based on structural similarities the P2Y receptor family is grouped into P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , and P2Y 11 receptors, and a dissimilar group containing P2Y 12 and P2Y 13 receptors (Kunapuli and Daniel, 1998; von Kugelgen and Wetter, 2000; Vassort, 2001; Jacobson et al., 2002) . These G-coupled receptors, or their mRNA's, have been localized to cardiomyocytes (Webb et al., 1996) , cardiac fibroblasts (Zheng et al., 1998) , and vascular smooth muscle and endothelium (Wang et al., 2002) , and are known to regulate the activity of multiple intracellular kinases (von Kugelgen and Wetter, 2000) to modify cellular function.
Relatively little work has been undertaken to delineate functions of P2Y purinoceptors in myocardial stress resistance and protection. Unfortunately, delineating contributions of individual P2 sub-types to functional responses in intact tissue is hampered by mixed selectivity's of agonists and (particularly) antagonists (von Kugelgen and Wetter, 2000; Jacobson et al., 2002) . While judicious choice of drug concentration can limit the range of receptor candidates, recent studies of cardiac protection have employed very high (3-100 µM) UTP concentrations (Ninomiya et al., 2002a; Yitzhaki et al., 2005) , sufficient to maximally activate P2Y 2 , P2Y 4 , and P2Y 6 receptors, and potentially activate P2Y 1 and P2Y 11 receptors at which UTP is generally considered a poor agonist (von Kugelgen and Wetter, 2000; Jacobson et al., 2002) . Here we employ a low UTP concentration applied here, these receptors should not be significantly activated. Furthermore, we observed no effects of P2Y 1 agonism with 2-MeSATP (see RESULTS). Finally, the 10 and 200 µM concentrations of the non-selective P2Y antagonist suramin shown to inhibit UTP-mediated protection (Fig. 1) should exert greatest effects at P2Y 2 , P2Y 1 (eliminated as a candidate due to lack of effect of 2-MeSATP) and P2Y 11 receptors (eliminated as a candidate owing to their insensitivity to 250 nM UTP). Collectively, the effects of 250 nM UTP and suramin, and lack of effect of 2-MeSATP, implicate P2Y 2 receptor involvement in UTP-dependent cardioprotection.
In contrast to our data, a prior study in rats found that myocardial P2Y activation alone does not generate protection, although endogenous P2 agonists apparently contributed to benefit with ischemic preconditioning (Ninomiya et al., 2002a (Ninomiya et al., , 2002b . Limitation of ischemic injury observed here ( Figs. 1 and 2 ) is consistent with UTP-mediated protection of hypoxic cardiomyocytes (Yitzhaki et al., 2005) . Furthermore, in the course of the current study Yitzhaki et al. (2006) published details of infarct-sparing effects of transient UTP pre-treatment in an in vivo rat model. These investigators found UTP reduced hypoxia-dependent mitochondrial Ca 2+ load in isolated myocytes, potentially underlying observed protection. Reasons for the lack of effect of UTP in the earlier study of Ninomiya et al. (2002a) vs. protection observed here and by Yitzhaki et al. (2006) are not known, although high UTP levels employed in prior studies raises the possibility of confounding effects of multiple P2Y sub-type activation. Moreover, Ninomiya et al. (2006) did not assess markers of cell death, and heart rate was uncontrolled, complicating interpretation of rate-dependent contractility.
Ischemic Accumulation of Interstitial Nucleotides. Cardiac microdialysis provides a useful
tool for monitoring accumulation of signalling compounds in the myocardial interstitium (Harrison et al., 1998; Peart and Headrick, 2000; Ninomiya et al., 2002b) . While some degree of tissue injury is unavoidable in microdialysis studies, and is perhaps exaggerated in small technically challenging models such as the mouse (Peart and Headrick, 2000) , our data nonetheless reveal substantial ischemia-specific elevations in UTP, ATP and ADP in cardiac microdialysate (Fig. 3) . Although prior studies have documented similar elevations in ATP and ADP in rat myocardium (Ninomiya et al., 2002b) , together with elevations in the related P1 agonist adenosine in rat and mouse hearts (Harrison et al., 1998; Peart and Headrick, 2000) , this is the first report of ischemic elevations in myocardial interstitial UTP. Recent observations of vascular accumulation of UTP in patients suffering myocardial ischemia are consistent with cardiac UTP release (Wihlborg et al., 2006) .
The source and identity of nucleotides released during ischemia remains unclear: nucleotides may be released from endothelium by G-coupled receptor activation (Yang et al., 1994) , from sympathetic and parasympathetic nerve endings (Burnstock and Kennedy, 1986) , and from cardiac myocytes during hypoxic or ischemic stress (Forrester and Williams, 1977; Clemens and Forrester, 1980) . The changes in interstitial nucleotides observed here could play a regulatory role during or following ischemia: interstitial UTP, ATP, or ADP may all activate G-coupled P2Y receptors (with ATP and ADP additionally modulating ion channel-coupled P2X purinoceptors) in coronary vessels (Strobaek et al., 1996; Wang et al., 2002) , cardiac fibroblasts (Zheng et al., 1998) , and myocytes (Webb et al., 1996) . Though it is problematic to estimate precise solute concentrations from microdialysate levels, our data suggest that low µM levels of UTP and ATP may be achieved with severe ischemic stress, sufficient to activate P2Y 2 receptors at which these nucleotides possess EC 50 values JPET #125815
2006). The drug MRS2159 is selective at P2X 1 receptors. It is worth noting that suramin and PPADS can exert effects on signal transduction and G-proteins (Freissmuth et al., 1996; Shehnaz et al., 2000) . However, the polar nature of the agents prevents them from crossing the cell membrane, minimizing these effects in intact tissue.
Detrimental effects of 200 µM suramin and 10-100 µM RB-2 on post-ischemic recovery (Figs.
1 and 4), together with lack of effect of PPADS and MRS2159, tend to support intrinsic activation of P2Y purinoceptors. Since suramin selectively blocks P2Y 2 vs. P2Y 4 receptors (at which it exhibits very poor potency) (von Kugelgen and Wetter, 2000; von Kugelgen, 2006) , inhibitory effects of this agent on both UTP-mediated protection and intrinsic ischemic tolerance support involvement of P2Y 2 receptors. Lack of effect of PPADS on ischemic outcome is also consistent with P2Y 2 involvement, as PPADS is most potent at P2Y 1 and possibly P2Y 6 receptors, but ineffective at rodent P2Y 4 and human P2Y 2 receptors (von Kugelgen and Wetter, 2000; von Kugelgen, 2006) . In contrast, RB-2 will more broadly antagonize P2Y receptor sub-types, and is also shown to impact on postischemic recovery at low and high concentrations (Fig. 4) . However, a complication in this interpretation relates to potential blockade of ecto-nucleotidase activity by suramin and other P2
antagonists.
Several studies confirm that different P2 antagonists may non-competitively inhibit ectonucleotidase activity in different species and tissues (Chen et al., 1996; Yegutkin and Burnstock, 2000) . Studying Mg 2+ -sensitive ecto-nucleotidase from rats, Yegutkin and Burnstock (2000) arrived at an IC 50 of 20-30 µM for suramin (with values of 50 µM for RB-2, and ~1 mM for PPADS). Chen et al. (1996) acquired IC 50 values of 40 to >100 µM for suramin in rat and mouse cells (and 15-20 µM for both RB-2 and PPADS). These inhibitory effects will limit responses mediated by hydrolysis products of extracellular nucleotides, which may be responsible (at least in part) for the detrimental actions of these agents during ischemia-reperfusion. In assessing this possibility, we examined responses to lower 10 µM concentrations of suramin and RB-2 (Figs. 1 and 4 ), which we reasoned should retain some P2 inhibitory efficacy but be less effective in inhibiting ecto-nucleotidases.
Curiously, though the lower RB-2 concentration still effectively impaired post-ischemic outcome, 10 µM suramin was without effect on the response to ischemia (Fig. 4) . This likely stems from differing inhibitory potencies of the two agents at different P2 receptors (see above), but may additionally reflect effects of suramin on other processes dictating post-ischemic outcome (including inhibition of ecto-nucleotidase activity) at high concentrations. In this regard, preliminary findings of Eckle et al. (2006) reveal that gene ablation of CD73 worsens outcome from ischemia in vivo, and we have recently confirmed that P1 receptor activation by endogenous adenosine (which is generated via CD73 activity) does limit injury during ischemia-reperfusion (Reichelt et al., 2005) . We must temper our conclusion then, that effects of the P2 antagonist suramin may involve a combination of receptor antagonism and/or inhibition of beneficial actions of ecto-nucleotidase activity. Future work might address the impact of these agents on interstitial accumulation of nucleotides and their hydrolysis products.
Injurious effects of suramin and RB-2 in ischemic myocardium have not been documented previously. The studies of Ninomiya and colleagues (20002a,b) in rat hearts do not report on effects of P2 antagonism alone, and in any case employ an index of post-ischemic outcome that is difficult to interpret (rate-dependent contractile function in un-paced hearts). However, other evidence does support endogenous P2 receptor activation or roles for nucleotides in ischemic myocardium: cardiac t-PA release during ischemia is modulated by endogenous nucleotides acting at P2Y receptors (Olivecrona et al., 2007) ; intrinsic P2 receptor activation contributes to preconditioning with transient ischemia (Ninomiya et al., 2002b) ; and as already noted, CD73 knockout may worsen ischemic tolerance (Eckle et al., 2006) , supporting a contribution of extracellular nucleotide hydrolysis to cardiac protection. Thus, there is evidence for roles of endogenous nucleotides in (Table 1) . Additionally, and perhaps related, the P2 agonist UTP elicited a small (albeit insignificant) decline in baseline flow. There is some prior support for P2Y-mediated smooth muscle constriction, in addition to dilation (Corr and Burnstock, 1991; Murthy and Makhlouf, 1998) , although substantial species differences exist in these responses. This may explain the modest dilatory effect of extremely high (50 µM) UTP reported by Ninomiya et al. (2002a) in rat hearts vs.
modest (insignificant) constriction observed with UTP in the mouse (Table 1) . Other studies report on novel UTP-sensitive coronary P2Y receptors exhibiting some properties relevant to the current observations (Hill and Sturek, 2002) , and support UTP-mediated coronary constriction (Matsumoto et al., 1997) . Rayment et al. (2007) most recently presented evidence for P2Y 2 -dependent UTPmediated coronary artery contraction, which is sensitive to suramin. Thus, despite P2-mediated endothelium-dependent dilation of intact vessels (Vials and Burnstock, 1994; Marrelli, 2001) , evidence also reveals a P2Y-mediated coronary constriction (Matsumoto et al., 1997; Sugimura et al., 2000) . This article has not been copyedited and formatted. The final version may differ from this version.
